PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsRibavirin
Virazole, Rebetol(ribavirin)
Cotronak, Rebetol, Ribavirin, Virazole (ribavirin) is a small molecule pharmaceutical. Ribavirin was first approved as Virazole on 1985-12-31. It is used to treat chronic hepatitis c, human adenovirus infections, respiratory syncytial virus infections, virus diseases, and west nile fever in the USA. It has been approved in Europe to treat chronic hepatitis c. The pharmaceutical is active against inosine-5'-monophosphate dehydrogenase 2 and inosine-5'-monophosphate dehydrogenase 1.
Download report
Favorite
COVID-19
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Ribavirin (discontinued: Copegus, Rebetol, Ribasphere, Ribavirin, Virazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ribavirin
Tradename
Company
Number
Date
Products
VIRAZOLEBausch Health CompaniesN-018859 DISCN1985-12-31
1 products, RLD
REBETOLMerck & CoN-020903 DISCN1998-06-03
2 products
COPEGUSRocheN-021511 DISCN2002-12-03
2 products, RLD
REBETOLMerck & CoN-021546 DISCN2003-07-29
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
ribavirinNew Drug Application2024-02-09
virazoleNew Drug Application2025-08-14
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
chronic hepatitis cEFO_0004220D019698B18.2
virus diseases—D014777B34
respiratory syncytial virus infectionsEFO_1001413D018357—
west nile feverEFO_0007545D014901A92.3
human adenovirus infectionsEFO_0007434D000258—
renal cell carcinomaEFO_0000376D002292—
colorectal neoplasms—D015179—
brain neoplasmsEFO_0003833D001932C71
hepatocellular carcinoma—D006528C22.0
essential thrombocythemia—D013920D47.3
Show 17 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AP: Antivirals for treatment of hcv infections
— J05AP01: Ribavirin
HCPCS
No data
Clinical
Clinical Trials
1118 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Congenital abnormalitiesD000013EFO_0003915Q89.9————11
Hepatitis cD006526—B19.2————11
Pregnancy complicationsD011248——————11
HepatitisD006505—K75.9————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRibavirin
INNribavirin
Description
Ribavirin is a white powder and exists in two polymorphic forms. Ribavirin is a 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. It has a role as an antimetabolite, an antiviral agent, an antiinfective agent and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is a 1-ribosyltriazole, an aromatic amide and a monocarboxylic acid amide. Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.
Classification
Small molecule
Drug classantivirals
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
Identifiers
PDB—
CAS-ID36791-04-5
RxCUI—
ChEMBL IDCHEMBL1643
ChEBI ID63580
PubChem CID37542
DrugBankDB00811
UNII ID49717AWG6K (ChemIDplus, GSRS)
Target
Agency Approved
IMPDH1
IMPDH1
Organism
Homo sapiens
Gene name
IMPDH1
Gene synonyms
IMPD1
NCBI Gene ID
3614
Protein name
inosine-5'-monophosphate dehydrogenase 1
Protein synonyms
IMP (inosine 5'-monophosphate) dehydrogenase 1, IMP (inosine monophosphate) dehydrogenase 1, IMPD 1, IMPDH 1, IMPDH-I
Uniprot ID
P20839
Mouse ortholog
Impdh1 (23917)
inosine-5'-monophosphate dehydrogenase 1 (P50096)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Ribavirin
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 37,680 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ribavirin, Virazole
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
95,748 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use